The main biomarker currently used for diagnosis of PCa is prostate-specific antigen (PSA) which harbors good diagnostic values, however cannot distinguish PCa from resembling milder prostate disorders like benign prostate hyperplasia (BPH) and prostatitis (5). Here, KLK3 is linked to urogenital neoplasm.